Debiopharm invests double-digit millions in GenePOC, specialized in the development of rapid diagnostic tests. GenePOC, which has just received CE marking for its first bacteriological test, will start commercialization in Europe this autumn, and Debiopharm will set up a future production line in Martigny. Click here for the details.
Click here to read the article.
GenePOC will attend the 68th AACC Annual Scientific Meeting & Clinical Lab Expo, July 31-August 4, 2016 to be held at the Pennsylvania Convention Center.
As the leading event for laboratory medicine worldwide, the 68th AACC Annual Scientific Meeting & Clinical Lab Expo is the place where breakthrough innovations in clinical testing and patient care are introduced to the healthcare world.
GenePOC will be in Booth #4270.
Come and join us, we will be pleased to meet you !
Read more about AACC 2016
GenePOC will attend the 8th Next Generation Dx Summit to be held at the Grand Hyatt in Washington, D.C. from August 23 to 26, 2016.
This event brings together more than 1,000 diagnostic professionals from around the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, the Next Generation Dx Summit promises to be a must-attend event to hear the latest announcements and developments in this rapidly evolving field.
GenePOC’s CEO, Patrice Allibert, will give a presentation on Tuesday, August 23, during the session “Enabling Point of Care Diagnostics”. Click here to read the full abstract.
GenePOC will also be in Booth #1908.
Come and join us, we will be pleased to meet you !
Read more about Next Generation Dx Summit 2016.
GenePOC will attend the ASM Microbe 2016 Conference from June 16 to 20, held in Boston, Massachusetts. Join us in booth 1628.
GenePOC Inc., a Canadian company developing cost-effective and rapid molecular devices to detect pathogen genes at Point-of-Care, is pleased to announce that its project, in partnership with Université Laval, was successful in securing funding from Genome Canada and Génome Québec through the Genomic Applications Partnership Program (GAPP).
The project, entitled “New test to rapidly diagnose infections”, aims to support the development and commercialization of two new tests for the rapid diagnostic of infections. The GAPP program partners academic researchers with “users” of genomics to support projects that address real world challenges and opportunities.
“This funding from the Canadian government provides an opportunity for GenePOC to leverage the broad genomic expertise from the labs of Dr Michel G. Bergeron” said Patrice Allibert, PhD, CEO GenePOC. “ The first two assays developed by GenePOC, namely Group B Strep (GBS) and Clostridium Difficile (C.diff.), are scheduled to enter clinical trials validation within the next weeks. This project will help accelerate the development of our assay menu and will increase the attractiveness of our offer.”
Click here to read the detailed press release and background information from Genome Canada.
Click here to read the press release from Génome Québec
Québec City, February 2, 2016 – GenePOC Inc. is proud to announce that it has obtained the certification ISO 13485:2003 for its Quality Management System for Medical Devices. Click here for the press release.
NEW YORK (from GenomeWeb – Madeleine Johnson) – Canadian firm GenePOC recently expanded its staff and intends to enter the molecular diagnostics market with a Group B Streptococcus assay at the end of the second quarter of 2016 and a Clostridium difficile assay in Q4 2016.
The company will initially launch the tests as CE-IVD products in Europe, and is aiming for US Food and Drug Administration approval of its platform and assays in late 2016.
To support these efforts, GenePOC received an undisclosed amount of private financing at the beginning of this year. Swiss development group Debiopharm Diagnostics is now the largest shareholder in GenePOC, with Montreal’s Emerillon Capital also providing investment.
“Since then, the company is progressing very rapidly,” Herbert Torfs, vice president of business development strategy, told GenomeWeb in an interview.
Read the full article >
Download a PDF version of the full article >
A Quebec City company on the cusp of a revolution in the field of medical diagnosis
Infectious disease diagnosis made fast and easy with GenePOC technology
Quebec City, February 11th, 2015 – It will soon be possible to diagnose and identify Clostridium difficile, Staphylococcus, Streptococcus, respiratory tract infections, sexually transmitted infections, and a variety of other infectious diseases much faster using cutting edge technology developed by GenePOC, a rapidly expanding Quebec City company.
Not only will it be much simpler to diagnose and identify the infectious agent, but there will also be a tremendous impact on patient health. The time period between a visit to a healthcare professional and the start of appropriate medical treatment will be reduced to an absolute minimum.
“We have perfected a technology that can detect pathogen genes right at the point of care. The screening tests we offer are truly a revolution in medicine, particularly in the field of infectious disease diagnosis,” explains Patrice Allibert, CEO of the company located in the Quebec Metro High Tech Park.
Entirely designed and developed in the provincial capital at the CHU Québec by teams led by Dr. M. G. Bergeron, this technology meets a real and urgent need. “Health specialists around the world need a fast, high-quality diagnostic tool to help them provide targeted treatment for infectious diseases and provide patients with the best possible care,” says Sébastien Chapdelaine, Vice President, R&D. “This is a big improvement in health care, because the GenePOC device can provide results in under an hour, which means patients can start getting treatment sooner,” adds Allibert.
Winner of the 2013 North America Frost & Sullivan Entrepreneurial Company of the Year Award in molecular diagnostics, GenePOC is experiencing strong growth. The company recently expanded its office space from 8,000 square feet to 15,000 square feet and is set to double its staff in the coming year. Some 20 new employees will join its current team of professionals to develop and launch this product on the market.
Source and information:
Rouillier Communication Marketing
418-780-5391, ext. 2203
GenePOC finalized its funding with two key investors.
Contact UsIf you have questions, comments or need more information concerning GenePOC, talk to one of our customer service representatives. We will be pleased to assist you.
Write360 Rue Franquet, Porte 3
Canada G1P 4N3
Call1 (418) 650-3535
Monday to Friday
8:00 a.m. to 5:00 p.m. EST